7-124840979-T-C
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 0P and 2B. BP4_Moderate
The NM_015450.3(POT1):āc.1363A>Gā(p.Ile455Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000219 in 1,594,682 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 12/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ā ).
Frequency
Consequence
NM_015450.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
POT1 | NM_015450.3 | c.1363A>G | p.Ile455Val | missense_variant | 14/19 | ENST00000357628.8 | NP_056265.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
POT1 | ENST00000357628.8 | c.1363A>G | p.Ile455Val | missense_variant | 14/19 | 2 | NM_015450.3 | ENSP00000350249 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000132 AC: 2AN: 152052Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000360 AC: 9AN: 249896Hom.: 0 AF XY: 0.0000518 AC XY: 7AN XY: 135152
GnomAD4 exome AF: 0.0000229 AC: 33AN: 1442630Hom.: 0 Cov.: 29 AF XY: 0.0000237 AC XY: 17AN XY: 718792
GnomAD4 genome AF: 0.0000132 AC: 2AN: 152052Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74262
ClinVar
Submissions by phenotype
POT1-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jul 16, 2024 | The POT1 c.1363A>G variant is predicted to result in the amino acid substitution p.Ile455Val. This variant has been reported in individuals with familial melanoma (Supplementary Table 4, Shi et al. 2014. PubMed ID: 24686846; Goldstein et al. 2023. PubMed ID: 36876055). This variant is reported in 0.0070% of alleles in individuals of European (non-Finnish) descent in gnomAD. This variant has been reported as a variant of uncertain significance in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/475039/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jan 09, 2023 | In silico analysis supports that this missense variant does not alter protein structure/function; Observed in individuals with familial cutaneous malignant melanoma in the published literature (Shi et al., 2014); This variant is associated with the following publications: (PMID: 24686846, 28393830) - |
Tumor predisposition syndrome 3 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 31, 2022 | This sequence change replaces isoleucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 455 of the POT1 protein (p.Ile455Val). This variant is present in population databases (rs776965979, gnomAD 0.007%). This variant has not been reported in the literature in individuals affected with POT1-related conditions. ClinVar contains an entry for this variant (Variation ID: 475039). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt POT1 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Hereditary cancer-predisposing syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 24, 2023 | The p.I455V variant (also known as c.1363A>G), located in coding exon 10 of the POT1 gene, results from an A to G substitution at nucleotide position 1363. The isoleucine at codon 455 is replaced by valine, an amino acid with highly similar properties. This alteration has been identified in multiple cases of familial melanoma (Shi J et al. Nat Genet, 2014 May;46:482-6; Goldstein AM et al. JAAD Int, 2023 Jun;11:43-51). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at